CLINICAL RESEARCH: PHARMACOTHERAPY OF HDL AND LDL
Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels
Michael H. Davidson, MD, FACC*,*,
James M. McKenney, PharmD ,
Charles L. Shear, DrPH and
James H. Revkin, MD, FACC
* Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois
Virginia Commonwealth University, Richmond, Virginia
Pfizer Global Research and Development, New London, Connecticut
* Reprint requests and correspondence:
Dr. Michael Davidson, Radiant Research, 515 North State Street, Suite 2700, Chicago, Illinois 60610. (Email: michaeldavidson{at}radiantresearch.com).
OBJECTIVES: This study was designed to evaluate the efficacy and safety of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, in subjects with low high-density lipoprotein cholesterol (HDL-C) levels.
BACKGROUND: Evidence suggests HDL-C is atheroprotective. A proven mechanism for increasing the level of HDL-C is the inhibition of CETP.
METHODS: A total of 162 subjects with below-average HDL-C (men <44 mg/dl; women <54 mg/dl) who were not taking lipid-modifying therapy were randomized to double-blind treatment with torcetrapib 10, 30, 60, or 90 mg/day or placebo ( 30 subjects per group).
RESULTS: The percent change from baseline to Week 8 with torcetrapib (least-squares mean difference from placebo) was dose-dependent and ranged from 9.0% to 54.5% for HDL-C (p  0.0001 for 30 mg and higher doses) and from 3.0% to –16.5% for low-density lipoprotein cholesterol (LDL-C) (p < 0.01 for 90-mg dose). Low-density lipoprotein cholesterol lowering was less in subjects with higher (>150 mg/dl) versus lower levels of baseline triglycerides; at 60 mg, the change in LDL-C was 0.1% versus –22.2% (p < 0.0001), respectively. Particle size for both HDL and LDL increased with torcetrapib. There were no dose-related increases in the frequency of adverse events. Significant blood pressure increases were noted in 2 of 140 subjects.
CONCLUSIONS: Torcetrapib resulted in substantial dose-dependent elevations in HDL-C, accompanied by moderate decreases in LDL-C at the higher doses. Torcetrapib was generally well tolerated.
|
Abbreviations and Acronyms
| | AE = adverse event | | apo = apolipoprotein | | CE = cholesteryl ester | | CETP = cholesteryl ester transfer protein | | CHD = coronary heart disease | | CVD = cardiovascular disease | | DBP = diastolic blood pressure | | HDL-C = high-density lipoprotein cholesterol | | LDL-C = low-density lipoprotein cholesterol | | NMR = nuclear magnetic resonance | | SBP = systolic blood pressure | | VLDL-C = very low-density lipoprotein cholesterol |
|
Related Article
-
Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
- Richard V. Milani and Carl J. Lavie
J. Am. Coll. Cardiol. 2006 48: 1791-1792.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Eur. Heart J.,
October 12, 2009;
(2009)
ehp399v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Hu, J. D. Dietz, C. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser
Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
Endocrinology,
May 1, 2009;
150(5):
2211 - 2219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mackness and M. Mackness
High-density lipoprotein: why all the fuss?
Ann Clin Biochem,
January 1, 2009;
46(1):
5 - 7.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vergeer, M. L. Bots, S. I. van Leuven, D. C. Basart, E. J. Sijbrands, G. W. Evans, D. E. Grobbee, F. L. Visseren, A. F. Stalenhoef, E. S. Stroes, et al.
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Circulation,
December 9, 2008;
118(24):
2515 - 2522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Circulation,
December 9, 2008;
118(24):
2506 - 2514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Davidson
Is LDL-C Passed Its Prime?: The Emerging Role of Non-HDL, LDL-P, and ApoB in CHD Risk Assessment
Arterioscler Thromb Vasc Biol,
September 1, 2008;
28(9):
1582 - 1583.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Psaty and T. Lumley
Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs
JAMA,
March 26, 2008;
299(12):
1474 - 1476.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. B. Jensen and J. Hampton
Early termination of drug trials
BMJ,
February 17, 2007;
334(7589):
326 - 326.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Tall, L. Yvan-Charvet, and N. Wang
The Failure of Torcetrapib: Was it the Molecule or the Mechanism?
Arterioscler Thromb Vasc Biol,
February 1, 2007;
27(2):
257 - 260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Milani and C. J. Lavie
Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1791 - 1792.
[Full Text]
[PDF]
|
|
|
|
